The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients Full Text
International Journal of Nephrology and Renovascular Disease, 05/30/2012
Shigematsu T et al. – Hyperphosphatemia has been shown to be involved not only in the onset and progression of secondary hyperparathyroidism but also in vascular calcification. In addition, it influences the clinical course of patients with chronic kidney disease. Phosphate (Pi) binder is required in the management of hyperphosphatemia, because dietary Pi restriction and Pi removal by hemodialysis alone are insufficient. Lanthanum carbonate, a powerful Pi binder, has a similar effect to aluminum hydroxide in reducing serum Pi levels.